首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   112325篇
  免费   7867篇
  国内免费   3298篇
耳鼻咽喉   558篇
儿科学   2860篇
妇产科学   2230篇
基础医学   17500篇
口腔科学   2170篇
临床医学   6803篇
内科学   19792篇
皮肤病学   1723篇
神经病学   13165篇
特种医学   2838篇
外国民族医学   22篇
外科学   10100篇
综合类   10366篇
现状与发展   10篇
预防医学   5066篇
眼科学   1043篇
药学   16797篇
  32篇
中国医学   2270篇
肿瘤学   8145篇
  2023年   1405篇
  2022年   2872篇
  2021年   3892篇
  2020年   3291篇
  2019年   4261篇
  2018年   4320篇
  2017年   3492篇
  2016年   3175篇
  2015年   3539篇
  2014年   5907篇
  2013年   7148篇
  2012年   5224篇
  2011年   5922篇
  2010年   4913篇
  2009年   5137篇
  2008年   5275篇
  2007年   4837篇
  2006年   4262篇
  2005年   3632篇
  2004年   3369篇
  2003年   3103篇
  2002年   2459篇
  2001年   2195篇
  2000年   1984篇
  1999年   1773篇
  1998年   1857篇
  1997年   1699篇
  1996年   1513篇
  1995年   1226篇
  1994年   1123篇
  1993年   965篇
  1992年   751篇
  1991年   710篇
  1990年   544篇
  1989年   469篇
  1988年   419篇
  1986年   373篇
  1985年   1366篇
  1984年   2102篇
  1983年   1287篇
  1982年   1478篇
  1981年   1390篇
  1980年   1122篇
  1979年   977篇
  1978年   859篇
  1977年   729篇
  1976年   824篇
  1975年   590篇
  1974年   511篇
  1973年   563篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
本实验探讨了内源性速激肽是否参与白三烯C4(LTC4)的气道效应.LTC4(0.5μgkg-1,iv)可增高豚鼠肺内压(IPP)和气道内依文思蓝渗出。速激肽NK-1受体拮抗剂CP-96345{(2S,3S)-顺式-2-(二苯甲基)-N-[(2-甲氧苯)-甲基]-1-杂氮双环[2.2.2]辛烷-3-胺}1mgkg-1,iv,可减弱LTC4诱导的依文思蓝渗出;NK-2受体拮抗剂SR-48968{(S)-N-甲基-N-[4-(4-乙酰氨基-4-苯基哌啶)-2-(3,4-二氯苯基)丁基]苯甲酰胺},1mgkg-1,iv,可抑制IPP的增高.白三烯拮抗剂ONO-1078(0.03mgkg-1,iv)可阻断这两种反应.结果说明内源性速激肽增强LTC4的气道作用,其中NK-1受体介导微血管渗漏,NK-2受体介导支气管收缩.  相似文献   
92.
Serotonin (5-HT) is a mediator (through 5-HT1P receptors) of slow EPSPs in myenteric ganglia of the small intestine. The effect of 5-HT can be mimicked by elevating cAMP; therefore, we tested the hypothesis that the slow EPSP-like response to 5-HT is cAMP-mediated. Guinea pig gut was enzymatically dissociated; myenteric ganglia remained intact and were collected by filtration. Neurons in the isolated ganglia retained their ability to manifest the slow EPSP-like response to 5-HT. Exposure to 5-HT raised the ganglionic level of cAMP (ED50 0.3 μM). This effect was not antagonized by the 5-HT1P antagonist, N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide (100.0 μM), or mimicked by the 5-HT1P agonist, 5-hydroxyindalpine (10.0 μM). Increases in cAMP were also evoked by the 5-HT1 agonist, 5-carboxyamidotryptamine (10.0 μM), the 5-HT2 agonist, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 1.0–10.0 μM), and by the 5-HT4 agonists, renzapride (1.0–10.0 μM) and 5-methoxytryptamine (1.0–10.0 μM); however, neither the 5-HT1/5-HT2 antagonists, spiperone, methysergide, and methiothepin, nor the 5-HT4 antagonist, tropisetron (ICS 205–930; 10.0 μM), were able to inhibit the rise in cAMP evoked by these compounds or by 5-HT (0.1–10.0 μM). The 5-HT-evoked elevation of cAMP was antagonized by ketanserin (10.0 μM), which also blocked the effects of 5-methoxytryptamine and DOI, but not those of renzapride. The effective concentration of DOI, however, was higher than that needed for activation of 5-HT2 receptors, and Northern analysis using a cDNA probe encoding the rat 5-HT2 receptor failed to reveal the presence of 5-HT2 mRNA in myenteric ganglia, although it hybridizes with mRNA of the right size in the guinea pig brain. Compounds that failed to change levels of cAMP or to antagonize the action of 5-HT included 8-hydroxy-di-n-propylamino tetralin, R58639, R88226, and sumatriptan. It is concluded that the receptor responsible for the 5-HT-induced rise in cAMP in ganglia isolated from the guinea pig myenteric plexus is not a known subtype of 5-HT receptor. Since the pharmacology of this novel receptor is different from that of the slow EPSP-like response to 5-HT, the receptor probably does not mediate the slow EPSP. © 1993 Wiley-Liss, Inc.  相似文献   
93.
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha(OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha(OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha (OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha(OH)D3 varied individually, but was in the range of 2-4 micrograms daily.  相似文献   
94.
目的研究不同剂量60Co γ射线辐照全血在保存期内红细胞CR1分子数目的变化.方法应用酶联法定量测定经15~35GY五个照射剂量辐照全血在保存期内红细胞CR1分子数目.结果照射后1d,15~25GY剂量组红细胞CR1分子数目相互间比较及分别与对照组比较无明显差异(P>0.05);经30、35GY辐照红细胞CR1分子数目分别与其他剂量组和对照组比较有明显差异(P<0.05~0.01).另外,随着保存期的延长,各剂量组和对照组红细胞CR1分子数目呈阶梯式下降,尤其在照射后3d,30和35GY剂量组红细胞CR1分子数目接近于照射后7d水平,二者相互比较无明显差异(P>0.05).结论在一定范围内(15~25GY)60Co γ射线剂量辐照对红细胞CR1分子数目无明显影响.  相似文献   
95.
The long-held belief that degeneration of the cholinergic basal forebrain was central to Alzheimer's disease (AD) pathogenesis and occurred early in the disease process has been questioned recently. In this regard, changes in some cholinergic basal forebrain (CBF) markers (e.g. the high affinity trkA receptor) but not others (e.g., cortical choline acetyltransferase [ChAT] activity, the number of ChAT and vesicular acetylcholine transporter-immunoreactive neurons) suggest specific phenotypic changes, but not frank neuronal degeneration, early in the disease process. The present study examined the expression of the low affinity p75 neurotrophin receptor (p75(NTR)), an excellent marker of CBF neurons, in postmortem tissue derived from clinically well-characterized individuals who have been classified as having no cognitive impairment (NCI), mild cognitive impairment (MCI), and mild AD. Relative to NCI individuals, a significant and similar reduction in the number of nucleus basalis p75(NTR)-immunoreactive neurons was seen in individuals with MCI (38%) and mild AD (43%). The number of p75(NTR)-immunoreactive nucleus basalis neurons was significantly correlated with performance on the Mini-Mental State Exam, a Global Cognitive Test score, as well as some individual tests of working memory and attention. These data, together with previous reports, support the concept that phenotypic changes, but not frank neuronal degeneration, occur early in cognitive decline. Although there was no difference in p75(NTR) CBF cell reduction between MCI and AD, it remains to be determined whether these findings lend support to the hypothesis that MCI is a prodromal stage of AD.  相似文献   
96.
短串联重复序列HumFGA、D3S1359的法医学应用研究   总被引:1,自引:0,他引:1  
对短串联重复序列(short tandem repeats,STR)的两个高多态位点HumFGA(human alpha fibrinogen,人类α-纤维蛋白原基因)、D3S1359的法医学应用进行研究,并通过实际检测案件统计结果进行评估。实验结果表明:两位点灵敏度高,分别为0.2、0.5ngDNA;同一性和可重复性均较理想;种属特异性好,常见动物未发现扩增产物,仅灵长类动物(黑叶猴和猕猴)有扩增条带;复合扩增体系效果良好;在352次减数分裂中,D3S1359未发现突变,HumFGA检测到1次,突变率为0.28%;实际案件统计和应用结果也显示两位点是多态性高,实用性强的两个遗传标记系统。HumFGA和D3S1359在法医学个人识别与亲子鉴定案例中有较大应用价值。  相似文献   
97.
98.
目的 :探讨低胆红素血症对机体抗氧化能力和脂质过氧化的不良影响并观察VitE的干预效果。方法 :从体检健康人群中有意选择 4 5例胆红素水平偏高者 (≥ 15 μmol/L)和 4 0例胆红素水平偏低者 (≤ 9μmol/L)作为研究对象 ,抽空腹静脉血检测血清总抗氧化能力 (T -AOC) ,丙二醛 (MDA)及血浆氧化修饰低密度脂蛋白(Ox -LDL) ,并给低胆红素组每人每天口服VitE 10 0mg ,连续 2周 ,复测上述指标。结果 :与高胆红素组比 ,低胆红素组T -AOC明显降低 (P <0 .0 1) ,而MDA和Ox -LDL明显升高 (P <0 .0 5和P <0 .0 1) ,但低胆红素组补充VitE干预后 ,T -AOC显著升高 ,而MDA和Ox -LDL显著降低 (均P <0 .0 1) ,分别达到甚至超过了高胆红素组的相应水平。结论 :低胆红素血症可显著降低机体抗氧化能力 ,促进脂质过氧化 ,但这一不良影响可以通过补充VitE得到有效纠正。  相似文献   
99.
100.
目的 :探讨血清可溶性白细胞介素 2受体 (sIL 2R)在慢性乙型病毒性肝炎 (慢乙肝 )中的发病机制及sIL 2R与肝纤维化指标、肝功能的相关关系。方法 :对 312例肝活检病人按组织病理学炎症和纤维化程度进行分级分期 ,同时检测了病人血清sIL 2R、肝功能及肝纤维化相关指标。结果 :血清sIL 2R均值较对照组明显增高 (P <0 .0 1) ,增幅随着肝脏病理炎症和纤维化程度的加重而逐渐加大 ,各组间比较差异有显著性 (P <0 .0 5或P <0 .0 1)。sIL 2R与血清白蛋白 (A)呈显著负相关 ,与血清脯氨酸肽酶 (PLD)、Ⅳ型胶原 (CⅣ )、层粘连蛋白 (LN)、透明质酸 (HA)、Ⅲ型前胶原氨基端肽 (PⅢNP)、肝功指标中的TB、DB、G、ALT、AST、AKP、γ GT呈显著正相关 (P <0 .0 5或P <0 .0 1)。结论 :慢乙肝病人血清sIL 2R水平与A呈显著负相关 ,与PLD、CⅣ、LN、HA、PⅢNP呈显著正相关 ;sIL 2R的血清水平能反映肝脏组织学病变的程度 ,可作为判断肝组织炎症和纤维化程度的参考指标。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号